Natrecor increases risk of death
After it was found that Natrecor may cause kidney damage, another study by Jonathan D. Sackner-Bernstein, MD; Marcin Kowalski, MD; Marshal Fox, MD; and Keith Aaronson, MD, MS shows that compared with noninotrope-based control therapy, nesiritide (or Natrecor) may be associated with an increased risk of death after treatment for acutely decompensated heart failure. The authors recommend that the possibility of an increased risk of death should be investigated in a large-scale, adequately powered, controlled trial before routine use of Natrecor for acutely decompensated heart failure.
The study has been published in the Journal of American Medical Association (JAMA). Nesiritide typically improves symptoms in patients with acutely decompensated heart failure compared with placebo and appears to be safer than dobutamine. Its short-term safety relative to standard diuretic and vasodilator therapies is less clear. The researchers decided to investigate the safety of Natrecor relative to noninotrope-based control therapies, primarily consisting of diuretics or vasodilators.
The data for the study came primarily from reports of completed clinical trials from the US Food and Drug Administration (FDA), the study sponsor (Scios Inc), a PubMed literature search using the terms nesiritide, clinical trials, and humans, and a manual search of annual meetings of 3 heart associations.
The study has been published in the Journal of American Medical Association (JAMA). Nesiritide typically improves symptoms in patients with acutely decompensated heart failure compared with placebo and appears to be safer than dobutamine. Its short-term safety relative to standard diuretic and vasodilator therapies is less clear. The researchers decided to investigate the safety of Natrecor relative to noninotrope-based control therapies, primarily consisting of diuretics or vasodilators.
The data for the study came primarily from reports of completed clinical trials from the US Food and Drug Administration (FDA), the study sponsor (Scios Inc), a PubMed literature search using the terms nesiritide, clinical trials, and humans, and a manual search of annual meetings of 3 heart associations.
<< Home